Exactech device recall MDL 3044: where the polyethylene oxidation litigation actually stands after the bankruptcy filing

The Exactech device recall litigation represents one of the most procedurally complex active mass torts due to the manufacturer's October 2024 Chapter 11 bankruptcy filing. MDL 3044 (In re: Exactech Polyethylene Orthopedic Products Liability Litigation), centralized in the U.S. District Court for the Eastern District of New York before Judge Nicholas Garaufis, consolidated approximately 1,460 federal cases alleging that Exactech knee, hip, and ankle implants were packaged in vacuum-sealed bags lacking the required ethylene vinyl alcohol (EVOH) oxygen barrier layer. The packaging defect allowed oxygen to permeate the bags during shelf storage, causing ultra-high molecular weight polyethylene (UHMWPE) inserts to oxidize and degrade before implantation. Once implanted, the degraded polyethylene wore prematurely, generating microscopic debris particles that caused osteolysis (bone loss) and implant loosening, ultimately requiring revision surgery.

The procedural posture has been substantially affected by Exactech's bankruptcy. Exactech, Inc. and its affiliated entities filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware in October 2024. The bankruptcy filing automatically stays litigation against the debtor under 11 U.S.C. §362. As of mid-2026, the MDL bellwether trials originally scheduled through late 2025 and early 2026 (Tarloff, Larson, Kramer, Caputo) have been stayed pending bankruptcy resolution. The litigation moved from active bellwether preparation to claims-administration limbo where plaintiffs must navigate both the MDL framework and the bankruptcy proceeding to preserve their rights.

The recall itself was substantial. Beginning in June 2021 and expanding through February 2022, Exactech recalled approximately 200,000 polyethylene knee, hip, and ankle devices manufactured between 2004 and August 2021. The FDA classified the recall as Class II. The recall covered:

• Optetrak knee system
• Logic knee system
• Truliant knee system
• Vantage ankle system
• Novation hip system
• AcuMatch hip system
• MCS hip system
• Connexion GXL hip liners

The substantive theory in the litigation has been straightforward — Exactech knew or should have known that its packaging didn't include the EVOH layer that protects polyethylene from oxidation, the deficiency caused premature device degradation, and the company failed to recall the affected products in a timely manner. Internal documents produced before the bankruptcy stay showed the company had information about packaging issues for years before the formal recall. The strength of the substantive case combined with the substantial number of affected patients (potentially many of the 200,000 device recipients) creates substantial liability exposure that the bankruptcy is now attempting to address through reorganization.

This is the science behind the polyethylene oxidation defect, the procedural history of MDL 3044 through the bankruptcy filing, the eligibility framework for current and prospective plaintiffs, the bankruptcy proceeding's effect on litigation, and the strategic considerations for affected patients navigating the unusual combined MDL-and-bankruptcy framework.

The polyethylene oxidation defect

Modern joint replacement implants use a combination of metal components and plastic (polyethylene) inserts:

The role of polyethylene in joint implants. Polyethylene serves as the bearing surface between metal components. The plastic insert acts as cartilage substitute, allowing the metal components to articulate smoothly without metal-on-metal contact. The polyethylene component is critical to the implant's function and longevity.

UHMWPE properties. Ultra-high molecular weight polyethylene (UHMWPE) is the standard material for joint implant bearing surfaces. The material has:

• Excellent wear resistance under normal conditions
• Low friction characteristics
• Biocompatibility
• Substantial structural strength

But UHMWPE has a critical vulnerability — it oxidizes when exposed to oxygen, particularly when irradiated for sterilization (a standard manufacturing step).

The oxidation problem. UHMWPE that has been gamma-irradiated for sterilization contains free radicals that react with oxygen over time:

• Oxygen exposure causes chemical breakdown of polymer chains
• Material becomes brittle and degrades mechanically
• Wear resistance is substantially reduced
• The degraded material breaks apart faster under joint stress
• Microscopic debris is generated by the accelerated wear

The EVOH barrier solution. Modern packaging for polyethylene implants uses vacuum-sealed bags with ethylene vinyl alcohol (EVOH) layer to prevent oxygen permeation. The EVOH layer:

• Blocks oxygen molecules from passing through packaging
• Maintains inert atmosphere around the implant
• Prevents pre-implantation oxidation
• Is standard practice in the orthopedic implant industry

Exactech's packaging defect. Exactech's vacuum-sealed packaging used non-conforming bags that LACKED the EVOH barrier layer. The absence allowed:

• Oxygen permeation through bag material
• Pre-implantation oxidation of the UHMWPE inserts
• Material degradation before patients ever received the implant
• Premature failure once implanted in patients

The defect dates back to approximately 2004 when Exactech apparently switched to the non-conforming packaging without recognizing or disclosing the oxygen barrier deficiency. The defect continued for approximately 17 years before the recall was issued.

Clinical consequences. Once implanted, the pre-oxidized polyethylene:

• Wears faster than normal polyethylene
• Generates wear debris particles
• Triggers immune response to the debris
• Causes osteolysis (bone tissue death/resorption) around the implant
• Results in implant loosening
• Causes pain, instability, and functional limitations
• Requires revision surgery (replacement of the failing implant)

The revision surgery for failed joint implants is substantially more complex than initial joint replacement. Revision involves:

• Removing the original implant (often with substantial bone damage)
• Cleaning the surgical site
• Often requires bone grafting to address osteolysis
• Implanting new components
• Extended recovery period
• Increased complication risk compared to initial surgery

The procedural history of MDL 3044

The litigation developed:

June 2021. Exactech initiated initial recall of Connexion GXL hip liners manufactured between 2015 and 2021. Notification to surgeons who had implanted these devices.

August 2021. Recall expanded to include additional Exactech polyethylene components.

February 2022. Recall expanded substantially to cover all knee and ankle inserts packaged in non-conforming bags lacking EVOH layer. Notification to surgeons of all polyethylene devices implanted since 2004.

Subsequent expansion. Additional approximately 40,000 hip devices added to recall. Notification expanded to include surgeons who had implanted Connexion GXL liners and "nonconforming conventional UHMWPE liners" since 2004.

Early federal lawsuit filings. Plaintiffs began filing federal lawsuits in 2021-2022 across various district courts.

June 2022. Motion to consolidate 27 federal Exactech cases presented to the Judicial Panel on Multidistrict Litigation. Weitz & Luxenberg led the consolidation petition.

October 7, 2022. MDL Panel approved consolidation. Cases transferred to Eastern District of New York before Judge Nicholas Garaufis. MDL designated as No. 3044.

Throughout 2022-2024. Active discovery, expert work, and case management orders. Plaintiff Fact Sheet (PFS) requirements established. Case count grew to approximately 1,460 federal cases.

April 2024. Bellwether trial cases selected per Case Management Order No. 2:

• First bellwether: Gayle Tarloff (originally June 2025)
• Second bellwether: Geraldine Larson (originally August 2025)

May 2024. Third and fourth bellwether selections per Case Management Order No. 3:

• Third bellwether: Dana Kessler Kramer (national pool, October 2025)
• Fourth bellwether: David Caputo (national pool, January 2026)

Late 2024. Discovery delays caused rescheduling. First two bellwethers rescheduled to September 29, 2025 (Tarloff) and November 10, 2025 (Larson). Judge Garaufis noted pretrial tasks wouldn't be finalized until at least January 2025.

October 2024. EXACTECH BANKRUPTCY FILING. Exactech, Inc. and affiliated entities filed Chapter 11 bankruptcy in U.S. Bankruptcy Court for the District of Delaware. The filing automatically stayed all civil litigation including MDL 3044 bellwether preparations.

Post-bankruptcy. All MDL litigation stayed. Bellwether trials cancelled. Plaintiffs face the complex task of filing claims in both the MDL framework and the bankruptcy proceeding to preserve their rights.

Florida state court track. Some Exactech cases were proceeding in Florida state courts (Exactech is headquartered in Florida). First Florida state case was set for trial in October 2024. State court cases face similar bankruptcy stay issues but may have different procedural posture.

2026 status. Litigation effectively frozen pending bankruptcy resolution. The bankruptcy proceeding addresses claims allocation across the substantial pool of affected patients. Resolution timeline uncertain but likely 2027-2028 for substantial claim payments.

The bankruptcy proceeding's effect

Exactech's Chapter 11 bankruptcy has fundamentally changed the litigation framework:

Automatic stay under 11 U.S.C. §362. The bankruptcy filing automatically stays:

• All pending civil litigation
• New lawsuit filings against the debtor
• Collection efforts on pre-bankruptcy claims
• Various other actions against the debtor

The stay protects the debtor from being forced to fight on multiple fronts during reorganization. The stay continues until the bankruptcy court lifts it or the case is resolved.

Claims process in bankruptcy. Plaintiffs (and potential plaintiffs) with claims against Exactech must file proofs of claim in the bankruptcy proceeding:

• Proof of claim form required
• Specific deadline established by bankruptcy court (bar date)
• Documentation supporting the claim
• Classification of claim (priority, secured, unsecured)

Filing in the bankruptcy proceeding is essential — failure to file by the bar date can result in claim disallowance.

Reorganization framework. Chapter 11 reorganization typically results in:

• Settlement framework for personal injury claims
• Funding mechanism for resolved claims
• Discharge of pre-bankruptcy claims after plan confirmation
• Restructured company emerging from bankruptcy

Claims trust. Mass tort bankruptcy reorganizations frequently establish claims trusts that:

• Receive funding from the reorganized company
• Process and pay claims according to established matrix
• Operate independent of the reorganized company
• Provide structured framework for compensation

Settlement matrix likely. Similar to other mass tort bankruptcies (Johnson & Johnson's failed talc bankruptcy attempts, 3M's failed Aearo bankruptcy), Exactech's bankruptcy reorganization is likely to establish:

• Tier-based compensation matrix
• Severity-based valuation
• Documentation requirements
• Procedural framework for claim review

MDL coordination. The MDL framework and bankruptcy proceeding will likely coordinate:

• Some procedural matters may continue in MDL
• Claim valuation framework developed in bankruptcy
• Class representative or settlement counsel may emerge from MDL leadership
• Settlement framework approval may involve both courts

Timeline implications. Chapter 11 reorganizations typically take 12-36 months. Plaintiffs should plan for 2-4 year timeline before substantial claim payments begin.

Eligibility framework

The framework for filing Exactech claims:

Implant identification. Documentation that an Exactech recalled device was used:

• Operative report from joint replacement surgery
• Implant card (if provided to patient)
• Hospital records identifying the specific device
• Surgeon records
• Recall notification letter (if received from Exactech)

Recalled device implantation. The implant must be one of the recalled devices manufactured between 2004 and 2022. The recall scope covers:

• All Exactech polyethylene knee, hip, and ankle inserts manufactured 2004-2022
• Connexion GXL hip liners 2015-2021
• Conventional UHMWPE liners manufactured under non-conforming packaging
• Various Exactech products through additional recall expansions

Qualifying injury. Documented complications from the device:

• Need for revision surgery (most common qualifying injury)
• Significant pain or functional impairment requiring medical intervention
• Documented evidence of accelerated wear or implant failure
• Bone loss (osteolysis) around the implant
• Implant loosening

Revision surgery as benchmark. The strongest cases involve documented revision surgery. The revision surgery establishes:

• Failure of the original implant
• Causation (the original implant failed due to polyethylene problems)
• Damages (cost and impact of revision surgery)
• Continuing medical needs

Cases without revision yet. Some patients have symptoms but haven't yet undergone revision. These cases face:

• Causation challenges (must establish device failure without revision evidence)
• Damages assessment more difficult
• Generally weaker than revision cases
• May be improved if revision becomes necessary later

Statute of limitations analysis. Most states have 2-4 year limitations periods. The discovery rule applies in many jurisdictions — limitations begins when patient knew or should have known about device failure, not when original implant occurred. The discovery rule can extend effective limitations periods substantially.

Bankruptcy bar date compliance. Plaintiffs must file proofs of claim in the bankruptcy proceeding by the established bar date. Missing the bar date can result in claim disallowance regardless of underlying merit.

The strongest typical case profile:

A patient who had joint replacement surgery (knee, hip, or ankle) with documented Exactech device implantation 2-15 years ago, developed implant complications requiring revision surgery, has comprehensive medical records documenting the original implantation through revision and recovery, received a recall notification letter, and is within the discovery-rule-extended statute of limitations period.

How Exactech compares to other recent mass torts

The litigation has distinctive features:

Compared to Bard hernia mesh MDL 2846 with multi-billion dollar settlement framework: Both involve medical device litigation with substantial documented internal corporate knowledge. Bard reached global settlement; Exactech entered bankruptcy. The procedural paths diverged based on defendant financial position.

Compared to Philips CPAP MDL 3014 which settled for $1.1 billion: Both involve medical device manufacturer recalls. Philips' parent company had financial capacity for settlement; Exactech's smaller size led to bankruptcy.

Compared to 3M Combat Arms earplugs MDL 2885 with $6 billion settlement after failed bankruptcy: 3M's Aearo Technologies bankruptcy attempt was dismissed by the bankruptcy court. 3M then settled the MDL directly. Exactech's bankruptcy is proceeding (unlike 3M's Aearo), creating different procedural dynamics.

Compared to Camp Lejeune water contamination which operates under specific statutory framework: Both involve substantial historical exposure with delayed legal accountability. Camp Lejeune uses specific statutory framework rather than typical MDL.

Compared to Ozempic GLP-1 MDL 3094 with substantial corporate defendants: Both involve substantial pharmaceutical/medical device litigation. Novo Nordisk and Eli Lilly have substantial financial capacity for eventual settlement; Exactech's smaller size led to bankruptcy.

Compared to NEC infant formula MDL 3026 with state court success: Both involve substantial documented defendants' internal knowledge. NEC has substantial state court verdicts; Exactech faces bankruptcy framework.

The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. Exactech represents the complex case where defendant bankruptcy substantially changes the procedural framework that would otherwise apply.

Strategic considerations

For affected patients and prospective plaintiffs:

File proof of claim in bankruptcy immediately. Regardless of MDL participation, plaintiffs must file proofs of claim in the Delaware bankruptcy proceeding by the established bar date. Missing the bar date is fatal to the claim.

Engage experienced counsel familiar with both MDL and bankruptcy. The current procedural framework requires expertise in:

• MDL practice
• Bankruptcy claims procedures
• Mass tort settlement matrices
• Joint legal/factual analysis

Counsel without both MDL and bankruptcy experience may miss critical procedural deadlines or claim valuation issues.

Document the medical timeline comprehensively. The strongest cases include:

• Original joint replacement operative report
• Exactech device identification (specific model, lot number when available)
• Complete medical records following implantation
• Documentation of complications and their development
• Revision surgery records (most important for case strength)
• Continuing treatment records

Watch for recall notification letters. If you received recall notification from Exactech (typically dated 2021-2023, with March 23, 2026 referenced for some notifications), this confirms you may have an affected device. Keep the notification letter as supporting documentation.

Verify the device implanted. Don't assume you have a recalled device:

• Check surgical records or implant card
• Contact the hospital or surgical center for records
• The hospital should have records identifying the specific manufacturer and model

Pursue revision surgery when medically indicated. If you have symptoms suggesting device failure (increasing pain, instability, decreased function), pursue medical evaluation. Imaging (X-rays, CT scans, MRI) can identify osteolysis and implant loosening. Revision surgery, when medically appropriate, both improves clinical outcome and strengthens the legal claim.

Watch the statute of limitations carefully. State-specific limitations periods apply. The discovery rule may extend effective limitations periods, but the analysis is case-specific. Cases involving recent recall notifications or recent symptom development may benefit from the discovery rule extension.

Be realistic about timeline. Bankruptcy reorganization typically takes 12-36 months. Substantial claim payments may not occur until 2027-2028 at earliest. Plan for extended timeline rather than expecting near-term resolution.

Don't accept inadequate pre-bankruptcy settlements. Some early Exactech settlements may have been offered before bankruptcy framework was clear. Pre-bankruptcy settlements typically don't include the full benefit of the bankruptcy claims framework. Have any settlement offer evaluated by counsel familiar with current procedural status.

Coordinate with treating physicians. Orthopedic surgeons who performed original joint replacement, revision surgeons, and ongoing treating physicians are important witnesses. Their support for the case theory and connection to Exactech devices strengthens cases substantially.

Consider state court alternatives. Some plaintiffs may benefit from state court filings (where available). Florida state court track may have different procedural dynamics. The strategic analysis depends on specific case facts.

Plan for the bankruptcy claims framework. The eventual bankruptcy resolution will likely establish:

• Tier-based compensation matrix
• Documentation requirements
• Procedural framework for claim review

Prepare comprehensive documentation now to support eventual tier assignment.

Watch for plan confirmation developments. The Chapter 11 plan confirmation process will determine the framework for claim resolution. Monitor proceedings through:

• Bankruptcy court docket
• Counsel updates
• Mass tort news sources

Don't lose track of the MDL framework. Even with the bankruptcy stay, MDL participation may matter for:

• Lead counsel participation in settlement negotiations
• Discovery materials availability
• Procedural framework when MDL resumes

For patients affected by Exactech device failures, the combined MDL-and-bankruptcy framework creates substantial procedural complexity. The substantive case theory remains strong — Exactech's packaging defect caused widespread premature device failure across thousands of patients. The eventual resolution through bankruptcy reorganization will likely produce meaningful compensation, but through a substantially more complex framework than the typical MDL settlement. The work for affected patients is in engagement with experienced counsel familiar with both MDL and bankruptcy procedures, comprehensive documentation of medical timeline, timely filing of bankruptcy claims, patience with the extended resolution timeline, and informed navigation of the unusual procedural framework. For patients with documented revision surgeries and strong medical records, the framework should eventually produce substantial compensation that addresses the medical costs, lost wages, and quality of life impact caused by the defective devices. The bankruptcy timeline is the primary constraint — affected patients should focus on positioning their claims effectively within the eventual settlement framework rather than expecting traditional litigation resolution paths.